Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stealthy NGM And Bristol Emerge As Serious NASH Competitors

Executive Summary

No longer quiet NGM Bio unveils Phase II data at EASL showing rapid and significant reductions of hepatic fat, while Bristol announces a partnership to produce a non-invasive diagnostic for NASH and presents promising Phase II data for its FGF21 analogue.


Related Content

Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron
Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity
IPO Update: Returns Sag As Seven More Biopharmas Go Public In September
Akero Thinks It Will Produce A Next-Wave Therapy For NASH With Former Amgen Compound
New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib
Madrigal's Early Phase IIb NASH Data Show Clinically Meaningful Fat Reduction
Genfit's Enrollment Delay In NASH May Aid Intercept's First-To-Market Goal
Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground
Combination Strategies A Common Thread In NASH R&D
NGM Aims For Three Drugs In Clinical Trials, Padded By Cash From Merck


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts